Literature DB >> 15190501

Sentinel lymph node dissection and the current status of American trials on breast lymphatic mapping.

Katherine E Posther1, Lee G Wilke, Armando E Giuliano.   

Abstract

The current national sentinel lymph node (SLN) clinical trials for breast carcinoma address the prognostic and therapeutic utility of SLN dissection (SLND) in women with early-stage, clinically node-negative breast cancer. Following completion of these studies, overall survival, disease-free survival, morbidity, and quality of life of patients will be compared. Surgeon participation is crucial to the ongoing success of clinical trials in the field of breast cancer surgery.

Entities:  

Mesh:

Year:  2004        PMID: 15190501     DOI: 10.1053/j.seminoncol.2004.03.019

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  4 in total

Review 1.  Sentinel lymph node mapping for primary breast cancer.

Authors:  Lori L Wilson; Armando E Giuliano
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

2.  Identification of lymphatic pathway involved in the spreading of prostate cancer by fluorescence navigation approach with intraoperatively injected indocyanine green.

Authors:  Shogo Inoue; Hiroaki Shiina; Naoko Arichi; Yozo Mitsui; Takeo Hiraoka; Koji Wake; Masahiro Sumura; Satoshi Honda; Hiroaki Yasumoto; Shinji Urakami; Akio Matsubara; Mikio Igawa
Journal:  Can Urol Assoc J       Date:  2011-08       Impact factor: 1.862

3.  Identification of lymphatic pathway involved in the spread of bladder cancer: Evidence obtained from fluorescence navigation with intraoperatively injected indocyanine green.

Authors:  Shogo Inoue; Hiroaki Shiina; Yozo Mitsui; Hiroaki Yasumoto; Akio Matsubara; Mikio Igawa
Journal:  Can Urol Assoc J       Date:  2013-05-13       Impact factor: 1.862

4.  Multimarker RT-PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients.

Authors:  A Nissan; D Jager; M Roystacher; D Prus; T Peretz; I Eisenberg; H R Freund; M Scanlan; G Ritter; L J Old; S Mitrani-Rosenbaum
Journal:  Br J Cancer       Date:  2006-03-13       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.